VanEck Associates’s Medifast MED Stock Holding History

VanEck Associates’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-275	Closed	-$53K	–	1394
2021 Q3	$53K	Buy	275 +102	+59%	+$25.1K	﹤0.01%	1231
2021 Q2	$49K	Buy	+173	New	+$46.9K	﹤0.01%	1202

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

VanEck Associates's MED Position: Q4 2021 in Review

VanEck Associates sold out of Medifast (MED) in Q4 2021, closing a stake of 275 shares — an estimated $53K sold.

VanEck Associates first reported a position in MED in Q2 2021 and held it in 2 quarters. The position peaked at $53K in Q3 2021. 297 funds tracked by Wall St. Rank hold MED as of Q4 2021.

VanEck Associates reported no remaining Medifast position as of Q4 2021 after selling out during the quarter.
VanEck Associates sold 275 Medifast shares in Q4 2021, an estimated $53K.
VanEck Associates first reported a position in Medifast in Q2 2021 and held it in 2 quarters.
VanEck Associates's Medifast position peaked at $53K in Q3 2021.
297 funds tracked by Wall St. Rank held Medifast as of Q4 2021.

Based on VanEck Associates's 13F filing for Q4 2021, filed 26 Jan 2022.